Article

Acquired immunodeficiency syndrome-related lymphoma. Simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial

Private Practice for Hematology, Oncology and Infectious Diseases, Bremen, Germany.
Cancer (Impact Factor: 4.9). 05/2006; 106(7):1560-8. DOI: 10.1002/cncr.21759
Source: PubMed

ABSTRACT Highly active antiretroviral therapy (HAART) has improved the survival of patients with acquired immunodeficiency syndrome-related lymphoma (ARL). The German ARL Study Group investigated whether HAART administered concomitantly with cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy compromised the course of immune parameters during and after chemotherapy and exerted a positive effect on remission and survival.
From 1997 to 2001, 72 patients with ARL were stratified prospectively into a standard-risk group (n = 48 patients) and a high-risk group (n = 24 patients) with either 0-1 or 2-3 of the following risk factors: CD4 < 50/microL, prior opportunistic infection, and/or a World Health Organization performance status > or = 3. Patients in the high-risk group received > or =75% of the CHOP regimen.
In the standard-risk group (CD4 = 223/muL; age-adjusted International Prognostic Index [aaIPI], 38% > or = 2), the complete remission (CR) rate was 79%, and median survival was not reached after a median 47 months of follow-up. CD4 counts did not change from baseline to 4 weeks after the end of chemotherapy (206/microL). In the high-risk group (CD4 = 34/muL; aaIPI, 88% > or = 2), the CR rate was 29%, and the median survival was 7.2 months (3 patients survived for > 3 yrs). Toxicity was moderate: Leukopenia Grade 3 or 4 occurred in 100 of 249 chemotherapy cycles (40%) in the standard-risk group and in 70 of 102 cycles (69%) in the high-risk group.
Based on the aaIPI, the survival of patients in the standard-risk group was very similar to that achieved by nonhuman immunodeficiency virus-infected patients who had aggressive lymphomas. Concurrent CHOP plus HAART can be administered in an outpatient setting. Thus, the authors recommend using this modality as first-line therapy for patients with ARL.

Download full-text

Full-text

Available from: Keikawus Arastéh, Sep 12, 2014
0 Followers
 · 
220 Views
 · 
19 Downloads
  • Source
    • "However, whether HAART should be used in chemotherapy synchronously is still under debate. Many scholars believe that the application of HAART in the process of chemotherapy is safe and effective [14, 15]. In this study, 6 patients chose chemotherapy. "
    [Show abstract] [Hide abstract]
    ABSTRACT: This work summarizes the clinical features and treatment of 10 AIDS patients with malignant lymphoma. A total of 10 AIDS patients with malignant lymphoma seen in Beijing Ditan Hospital since 2009 were enrolled. Clinical manifestations, pathological examinations, immunity levels, Epstein-Barr virus antibody examinations, complications, treatments, and outcomes were retrospectively analyzed. The main clinical manifestations of these patients included intermittent fever in 2 cases, neck masses and fever in 3 cases, auxiliary lymph node enlargement in 2 cases, and abdominal pain and bloating with fever in 3 cases. Up to 7 patients were pathologically diagnosed with diffuse large B cell lymphoma (DLBCL), and 3 patients were pathologically diagnosed with Burkitt's lymphoma. Up to 8 patients had CD4 cell counts below 200/µL, and 2 patients had a level of more than 200/µL. Up to 7 patients were negative for EBV-IgM antibodies and 3 patients were not examined. Six patients underwent different chemotherapy and their prognoses were different. One patient with Burkitt's lymphoma alternatively took CODOXM and IVAC for 3 turns after VP chemotherapy; 1 patient with liver metastasis took R-CHOP 5 times, then changed therapy regimen to R-MINE and MINE. One patient with adrenal DLBCL took CHOP 6 times. Three patients with DLBCL took CHOP 1 or 2 times. Four patients gave up treatment. Various infections and side effects occurred, including bone marrow suppression, gastrointestinal bleeding, and renal dysfunction during chemotherapy. Six patients took HAART, and 4 did not. Six patients died, whereas 3 patients got improved; and 1 patient was discharged. AIDS patients with malignant lymphoma had various clinical manifestations, were immunocompromised, and had multiple metastases when they were admitted; they were already in the interim or late stage of lymphoma. Chemotherapy was not effective, and additional complications occurred. HAART failed to improve patient prognosis, and the overall prognosis was poor.
    Cancer Biology and Medicine 06/2012; 9(2):115-119. DOI:10.3969/j.issn.2095-3941.2012.02.006
  • Source
    • "Interestingly, these HLTCs lost Fas surface and caspase-3 intracellular expression, were resistant to Fas-and doxorubicin (Dox)-induced apoptosis [1] and contained large multilamellar bodies with lysosomal features [2]. Dox is a DNA-damaging drug used in the clinical treatment of leukemia and other cancers [3] [4] [5]. Dox-induced apoptosis through the so-called ''intrinsic pathway'' is characterized by the disruption of the mitochondrial membrane potential (DWm) and subsequent activation of the caspase cascade. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Drugs containing the quinone group were tested on hyperproliferative leukemia T cells (HLTC: Jhp and Jws) and parental Jurkat cells. Doxorubicin, menadione and adaphostin produced different effects on these cell lines. Rapid doxorubicin-induced cell death in Jurkat cells was mediated by caspase activation. Doxorubicin-induced cell death of HLTCs was delayed due to the absence of caspase-3 and -8 expression. Delayed HLTC cell death was mediated and triggered by the generation of reactive oxygen species (ROS). Other drugs containing quinone groups, such as menadione and adaphostin, were also tested on HLTC and both were toxic by a caspase-independent mechanism. The toxicity of these drugs correlated with the generation of the superoxide anion, which increased and was more effective in HLTCs than in parental Jurkat cells. Accordingly, SOD1 activity was much lower in HLTCs than in Jurkat cells. This lower SOD1 activity in HLTCs was associated not only with the absence of the wild-type (16 kDa) SOD1 monomer but also with the presence of a shortened (14 kDa) SOD1 monomer isoform. Moreover, the cytotoxicity of drugs containing the quinone group was prevented by incubation with manganese(III) tetrakis (4-benzoic acid) porphyrin (MnTBAP), a cell-permeable superoxide dismutase mimetic and a potent inhibitor of oxidation. These findings could explain the sensitivity of HLTCs to drugs containing the quinone group using a mechanism dependent on oxidative stress. These observations can also be useful to target hyperproliferative leukemias that are resistant to the classical caspase-dependent apoptotic pathway.
    Chemico-biological interactions 05/2012; 198(1-3):18-28. DOI:10.1016/j.cbi.2012.05.001 · 2.98 Impact Factor
  • Source
    • "Some novel chemotherapeautic interventions in the treatment of AIDS-related lymphoma have shown promise, with improved outcomes reported, after combination therapies of HAART and different chemotherapeautic agents. The immune reconstitution inflammatory syndrome (IRIS) following HAART in AIDS-related lymphoma after receiving chemotherapy and antiretroviral therapy is evidence of improved immunity and may also signify better outcomes (Phatak et al., 2010; Weiss et al., 2006 ). "
    HIV-infection - Impact, Awareness and Social Implications of living with HIV/AIDS, 10/2011; , ISBN: 978-953-307-343-9
Show more